- CH₣252.66bn
- CH₣285.31bn
- $56.33bn
Amgen's autoimmune drug succeeds in late-stage trial (updated)
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
European drugmakers call for faster trials, more spending to compete with US, China
Corrected: Amgen's autoimmune drug succeeds in late-stage trial
Big Pharma growth malady has a risky cure
Brief: Novartis Says CHMP Of European Medicines Agency (EMA) Adopted Positive Opinion Recommending Marketing Authorization For Cosentyx
Anthropic quietly sets up biology lab as it ramps AI drug program
Anthropic quietly sets up biology lab as it ramps AI drug program
India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Swiss stocks - Factors to watch on September 17
Novartis halts ALS drug development after mid-stage trial failure (updated)
Brief: Novartis AG Discontinues Development Of VHB937 In Amyotrophic Lateral Sclerosis
Novartis experimental drug for ALS fails, Bloomberg News reports
Brief: Novartis Experimental Drug For ALS Fails In Another Pipeline Hit- Bloomberg News
Legend Biotech taps Novartis veteran Zhang as CEO (updated)
L'Oreal steals French stock market crown from LVMH (updated)
Legend Biotech taps Novartis veteran Zhang as CEO
US stocks weekly: Yields bite